Nurix Therapeutics presented new clinical data from the ongoing Phase 1a/1b NX-5948-301 study of bexobrutideg in patients with relapsed or refractory B-cell malignancies at the ASH Annual Meeting.
The data showed an objective response rate of 83% in CLL patients in the Phase 1a study.
The median progression free survival across all doses tested was 22.1 months.
Objective Response Rate of 83%
Including two complete responses in CLL patients in Phase 1a study.
Emerging Data on Phase 1b Cohorts
Higher ORR and longer progression free survival at the 600 mg recommended Phase 2 dose compared to 200 mg dose.
Safety Profile of Bexobrutideg
Consistent safety profile observed between the 600 mg RP2D and the overall study population.
- The data demonstrates compelling efficacy and durability of bexobrutideg for patients with relapsed or refractory CLL/SLL.
- Advancing the 600 mg dose into the pivotal DAYBreak program reflects confidence in sustained clinical benefit with a favorable safety profile.
The presented data supports the continued evaluation of bexobrutideg as a therapeutic approach for patients with relapsed or refractory CLL/SLL, offering promising outcomes and safety.